At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- JNJ-90301900 (drug), Durvalumab (biological), Concurrent Chemo/Radiation Therapy (cCRT) (radiation), Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin (drug)
- How long the study runs
- Study runs about 48 months (dates as stated)
- About the drug or intervention
- JNJ-90301900 — drug: JNJ-90301900 will be injected intratumorally and/or intranodally. · Durvalumab — biological: Durvalumab will be administered as intravenous (IV) infusion as cIT. · Concurrent Chemo/Radiation Therapy (cCRT) — radiation: Radiation by intensity modulated radiation therapy (IMRT) will be administered. · Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin — drug: Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy. · Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel — drug: Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 130
- Started
- 2024-12-06
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for carcinoma, non-small-cell lung
- • Phase2 - 130 participants
- • The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with carcinoma, non-small-cell lung
Where?
- • London - University College London Hospitals
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months...
- ✓Have that has grown locally unresectable stage III NSCLC according to the eighth edition lung cancer stage classification
- ✓Have an activity scale (ECOG) performance status of 0 to 1
Who cannot take part
- ✗Medical history of: (a) Primary immunodeficiency (b) Organ transplant that requires therapeutic immunosuppression
- ✗Another concurrent or prior primary cancer within the last 36 months at agreement to take part
- ✗Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900 crystalline solution,...
See the full criteria
Where Is This Study? (1 UK site)
University College London Hospitals
London NW1 2BU, United Kingdom
Rajinder Sidhu - Associate Director, Research Governance and Operations
uclh.jro-communications@nhs.net020 3447 9825How to Get in Touch
Study Contact
Sponsor contactCONTACT
